Immunovant, Inc.
IMVT
Kedudukan dalam Saham
#3089
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Harga Saham
$28.22
Modal Pasaran
$5.83B
Perubahan (1 hari)
-1.29%
Perubahan (1 tahun)
46.75%
Negara
US
Perdagangan Immunovant, Inc. (IMVT)
Kategori
Healthcare
Sejarah pecahan saham untuk Immunovant, Inc. (IMVT)
Saham Immunovant, Inc. (simbol: IMVT) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham IMVT yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham IMVT.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham IMVT yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham IMVT.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
